Sativex® (GW Pharmaceuticals, UK) is a cannabis-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (into the mouth) spray.Because of the use of whole extracts, non-standardized amounts of ballast components are also present, such as minor cannabinoids and terpenoids. Sativex has been approved in Canada as adjunctive treatment for neuropathic pain in adults with multiple sclerosis (MS) and in cancer pain.registration is pending in several European countries.
Uruguay: Course on Cannabis in Medicine.
USA: Cannabis Quality, 19-21 July 2016, Los Angeles.
France: Conference of the UFCM, 21 October 2016, Strasbourg.
Switzerland: Conference of the SACM 2016, 12 November 2016, Bern.
Israël: The International Medical Cannabis Conference, 11-13 September, 2016
The Cannabinoid Conference 2017 of the IACM, 29-30 September 2017, Cologne, Allemagne.
Déclaration des Droits de l’Homme en faveur de l’accès médical au cannabis et aux cannabinoïdes
A new article in Cannabinoids by Jacob Erkelens and Arno Hazekamp on Cannabis Indica.
IACM on Twitter
Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.